José María Jimeno

Dr. Jimeno rejoined PharmaMar in 2020 in the virology unit. He is a medical oncologist, and holds a PhD from the University of Barcelona. From 2015, Dr. Jimeno served as Chief Medical Officer at Phosplatin Therapeutics, and remains part of its Scientific Advisory. He was formerly VP of Clinical and Scientific Development at PharmaMar, responsible for developing Yondelis, which is approved in over 80 countries including the US and EU, and the development of Aplidin which is approved in Australia for multiple myeloma. Previously he worked at Farmitalia Carlo Erba and US Biosciences. Most recently, Dr Jimeno was co-founder and CEO of Pangaea Biotech, a cancer diagnostics company where he was involved in developing their EGFR diagnostic approved by the FDA. Dr. Jimeno has published over 100 papers in peer review journals on cancer and is a guest lecturer in immunology at The University of Zaragoza in Spain.